Annual Report 2024

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2024 83 The United Laboratories International Holdings Limited Annual Report 2024 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information HKFRS 8 Operating Segments requires operating segments to be identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker (“CODM”) (i.e. executive directors of the Company) for the purpose of allocating resources to segments and assessing their performance. The three revenue streams are the operating and reportable segments of the Group on which the Group reports its primary segment information. (a) Segment revenue and results Year ended 31 December 2024 Intermediate Bulk Finished Segments products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 2,658,691 6,372,683 4,727,563 13,758,937 – 13,758,937 Inter-segment sales 3,198,429 979,071 – 4,177,500 (4,177,500) – Segment revenue 5,857,120 7,351,754 4,727,563 17,936,437 (4,177,500) 13,758,937 Segment profit before research and development expenses 2,215,316 904,596 889,307 4,009,219 Research and development expenses (included in the measurement of segment profit) (113,881) (199,648) (577,228) (890,757) RESULT Segment profit 2,101,435 704,948 312,079 3,118,462 Share of results of an associate (192) Unallocated other income 136,300 Unallocated corporate expenses (114,871) Unallocated other gains and losses, net 184,325 Impairment losses under expected credit loss model, net (168) Finance costs (34,958) Profit before taxation 3,288,898